TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A federal settlement announced Oct. 13 requires CVS to block controlled-substance prescriptions from certain prescribers, including those with unresolved concerns after review. The agreement requires reporting on blocked prescribers but does not expressly require assessing what happens to their patients; the clinical effects remain unknown.
A $315 million settlement announced Oct. 13 requires CVS to block controlled-substance prescriptions from certain prescribers, including clinicians whose prescribing concerns remain unresolved after review. The agreement resolves federal allegations without an admission of liability, and its requirements do not expressly call for assessing whether affected patients subsequently receive appropriate care.
A memorandum accompanying the settlement requires CVS to block prescriptions from prescribers whose Drug Enforcement Administration registration or state license has been suspended or revoked. It also requires CVS to block a prescriber across its retail pharmacies when concerns identified in a review remain unresolved, unless the law prohibits the block. CVS must report blocked prescribers.
The settlement addresses alleged unlawful dispensing and false claims. Federal allegations are allegations, not findings of liability in the settlement; CVS did not admit liability under the agreement. The reporting requirement concerns the prescribers blocked, and the memorandum does not expressly require CVS to follow patients’ health outcomes after those restrictions take effect.
In an Oct. 21 MedPage Today commentary, Alex Smolak, PhD, argues that evaluation should include the care patients receive after a block. A restriction may stop dispensing through CVS, but patients’ pain, physical dependence or opioid use disorder may remain. The article proposes linking pharmacy and medical claims, potentially starting with one insurer’s population, to examine treatment gaps, later dispensing and emergency visits.
Patient Care After a CVS Block
A block can prevent a pharmacy from dispensing prescriptions from a prescriber flagged under the agreement. But reduced dispensing alone cannot show whether the intervention improved patient safety. Patients might find safer treatment elsewhere, continue a dangerous regimen through another pharmacy, or face a prolonged interruption in care.
Those outcomes matter because patients connected to the same prescriber can have different diagnoses, treatment histories and access to alternatives. Some may need reassessment; others may require support for physical dependence or treatment for opioid use disorder. A restriction on dispensing does not itself provide those services. The settlement’s reporting requirements offer a way to track prescriber blocks, but the stated terms do not expressly require measuring these patient-level effects.
As an affiliate, we earn on qualifying purchases.
Prior Safeguards and Opioid Risks
The commentary says comparable provisions appeared in a 2022 multistate settlement involving CVS, making the latest agreement a continuation of an established approach rather than a wholly new form of restriction. It frames the policy question as whether blocking unsafe dispensing is accompanied by a safe handoff to other care.
Smolak cites FDA warnings about severe withdrawal, uncontrolled pain and suicide after rapid opioid dose reduction or abrupt discontinuation in physically dependent patients. He also points to CDC guidance cautioning against rigid restrictions and patient abandonment. A large observational study in JAMA found that tapering among patients on stable, long-term, higher-dose opioids was associated with increased rates of overdose and mental-health crises.
Those findings do not establish that pharmacy blocks cause the same outcomes. A pharmacy block is not the same intervention as tapering a dose, and patients may obtain appropriate treatment elsewhere. The evidence identifies possible risks of treatment disruption, not a measured effect of CVS’s block policy.
“Stopping harmful prescribing and reducing the patient’s overall risk belong in the same intervention.”
— Alex Smolak, PhD, in a MedPage Today commentary
As an affiliate, we earn on qualifying purchases.
Patient Outcomes Are Not Tracked
The settlement memorandum does not expressly require an assessment of patients’ health after their prescriber is blocked. The available source material does not report how many patients may be affected, how often they obtain care elsewhere, or whether the blocks have changed overdose, emergency-visit or other health outcomes.
Any later evaluation would face limits. Claims data may miss pain, functioning and care outside insurance coverage. Patients of blocked prescribers may also have had higher risks before the restriction because of their health or treatment circumstances. An adverse event after a block would not, by itself, show that the block caused it. Clinical records and patient accounts could add information, but the source does not describe an evaluation already underway.
medication adherence pill organizer
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Evaluating Care After Restrictions
Smolak proposes an independent evaluation that links CVS block dates with pharmacy and medical claims. Researchers could identify patients who previously filled opioid prescriptions at CVS from blocked prescribers, then track subsequent treatment across care settings. The proposed measures include treatment gaps, later dispensing and emergency visits, compared with carefully selected patients and prior trends.
The proposal is not described as a settlement requirement or an active study. A useful assessment would need to account for why a prescriber was blocked and for patients’ pre-existing risks, while recognizing that claims do not capture every aspect of care. The source does not identify a deadline, responsible evaluator or next formal milestone. Whether CVS or other parties will conduct such a study remains unclear.
As an affiliate, we earn on qualifying purchases.
Key Questions
What does the CVS settlement require?
It requires CVS to block controlled-substance prescriptions from prescribers whose DEA registration or state license has been suspended or revoked, and from prescribers with unresolved concerns after review, unless law prohibits the block. CVS must report blocked prescribers.
Does the settlement require CVS to track affected patients?
The memorandum described in the source requires reporting on blocked prescribers but does not expressly require assessment of patients’ subsequent health outcomes.
Does a CVS block mean a patient cannot get treatment?
Not necessarily. The restriction applies to dispensing through CVS for prescriptions from the blocked prescriber. The source says patients may receive care elsewhere, but it does not establish how often that happens.
Does research show that these blocks cause harm?
No such finding is reported. Evidence cited in the commentary concerns opioid tapering and treatment disruption, not CVS prescriber blocks. Smolak says those studies identify potential concerns but do not establish that blocks cause similar outcomes.
What evaluation is being proposed?
Smolak proposes independently linking block dates with pharmacy and medical claims to track treatment gaps, later dispensing and emergency visits. The source presents this as a proposal, not a study already required or underway.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
